Los Angeles Capital Management’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$10.2M Sell
73,460
-3,095,415
-98% -$433M 0.04% 252
2025
Q4
$375M Sell
3,168,875
-676,504
-18% -$82.2M 1.28% 11
2025
Q3
$427M Buy
3,845,379
+1,223,895
+47% +$139M 1.45% 11
2025
Q2
$291M Buy
2,621,484
+98,448
+4% +$10.5M 1.09% 15
2025
Q1
$283M Buy
2,523,036
+2,040,261
+423% +$211M 1.25% 14
2024
Q4
$44.6M Buy
482,775
+65,722
+16% +$5.92M 0.18% 114
2024
Q3
$35M Sell
417,053
-261,936
-39% -$20M 0.14% 131
2024
Q2
$46.6M Sell
678,989
-738,365
-52% -$49.3M 0.17% 113
2024
Q1
$104M Sell
1,417,354
-19,677
-1% -$1.51M 0.35% 62
2023
Q4
$116M Buy
1,437,031
+501,105
+54% +$39M 0.43% 55
2023
Q3
$70.1M Buy
935,926
+634,659
+211% +$48.8M 0.3% 69
2023
Q2
$23.2M Sell
301,267
-228,813
-43% -$18.2M 0.09% 177
2023
Q1
$44M Sell
530,080
-1,755,157
-77% -$145M 0.2% 119
2022
Q4
$196M Buy
2,285,237
+155,507
+7% +$12.3M 0.95% 23
2022
Q3
$131M Buy
2,129,730
+155,376
+8% +$9.8M 0.68% 31
2022
Q2
$122M Sell
1,974,354
-7,654
-0.4% -$474K 0.6% 35
2022
Q1
$118M Buy
1,982,008
+752,594
+61% +$48.1M 0.46% 45
2021
Q4
$89.3M Buy
1,229,414
+641,141
+109% +$44.2M 0.33% 69
2021
Q3
$41.1M Sell
588,273
-122,198
-17% -$8.58M 0.19% 110
2021
Q2
$48.9M Sell
710,471
-87,329
-11% -$5.83M 0.22% 107
2021
Q1
$51.6M Buy
797,800
+320,409
+67% +$20.7M 0.23% 101
2020
Q4
$27.8M Sell
477,391
-113
-0% -$6.82K 0.12% 160
2020
Q3
$30.2M Buy
477,504
+84,916
+22% +$5.89M 0.14% 131
2020
Q2
$30.2M Buy
392,588
+239,647
+157% +$18.4M 0.15% 149
2020
Q1
$11.4M Sell
152,941
-353,974
-70% -$24.5M 0.07% 224
2019
Q4
$32.9M Buy
506,915
+88,599
+21% +$5.77M 0.16% 132
2019
Q3
$26.5M Sell
418,316
-1,627
-0.4% -$106K 0.14% 146
2019
Q2
$28.4M Sell
419,943
-196,105
-32% -$12.9M 0.15% 147
2019
Q1
$40M Sell
616,048
-817,276
-57% -$54.3M 0.22% 110
2018
Q4
$89.7M Buy
1,433,324
+901,998
+170% +$63M 0.56% 38
2018
Q3
$41M Sell
531,326
-466,330
-47% -$35.2M 0.22% 119
2018
Q2
$70.7M Buy
997,656
+940,044
+1,632% +$66.4M 0.39% 43
2018
Q1
$4.34M Sell
57,612
-502,974
-90% -$40M 0.02% 459
2017
Q4
$40.2M Buy
560,586
+237,987
+74% +$18.1M 0.22% 124
2017
Q3
$26.1M Buy
322,599
+190,898
+145% +$14.6M 0.15% 176
2017
Q2
$9.32M Sell
131,701
-2,417,591
-95% -$161M 0.06% 333
2017
Q1
$173M Buy
2,549,292
+1,092,206
+75% +$76.8M 1.26% 5
2016
Q4
$104M Buy
1,457,086
+851,028
+140% +$63.3M 0.82% 18
2016
Q3
$48M Buy
606,058
+577,552
+2,026% +$46.9M 0.4% 61
2016
Q2
$2.38M Sell
28,506
-1,115,764
-98% -$99M 0.02% 509
2016
Q1
$105M Buy
1,144,270
+239,856
+27% +$21.6M 0.94% 18
2015
Q4
$91.5M Buy
904,414
+391,704
+76% +$40.8M 0.84% 19
2015
Q3
$50.3M Buy
512,710
+177,090
+53% +$19.7M 0.49% 47
2015
Q2
$39.3M Sell
335,620
-204,566
-38% -$22.4M 0.37% 77
2015
Q1
$53M Sell
540,186
-480,961
-47% -$48.8M 0.49% 50
2014
Q4
$96.3M Buy
1,021,147
+183,586
+22% +$19M 0.88% 20
2014
Q3
$89.2M Sell
837,561
-262,675
-24% -$25.7M 1.08% 10
2014
Q2
$91.2M Buy
1,100,236
+67,990
+7% +$5.29M 0.88% 11
2014
Q1
$73.1M Buy
1,032,246
+677,547
+191% +$53.1M 0.8% 16
2013
Q4
$26.6M Sell
354,699
-435,447
-55% -$30.3M 0.3% 103
2013
Q3
$49.7M Buy
790,146
+140,616
+22% +$8.4M 0.61% 29
2013
Q2
$33.3M Buy
+649,530
New +$33.9M 0.47% 41

Other funds holding GILD

Los Angeles Capital Management's GILD Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Gilead Sciences (GILD) stake by 98% in Q1 2026, selling an estimated $433M and leaving 73,460 shares worth $10.2M. The position accounts for 0.04% of the portfolio, ranked #252.

Los Angeles Capital Management first reported a position in GILD in Q2 2013 and has held it in 52 quarters since. The position peaked at $427M in Q3 2025. 2,311 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Los Angeles Capital Management held 73,460 shares of Gilead Sciences worth $10.2M as of Q1 2026.
  • Los Angeles Capital Management sold 3,095,415 Gilead Sciences shares in Q1 2026, an estimated $433M.
  • Gilead Sciences made up 0.04% of Los Angeles Capital Management's portfolio in Q1 2026, its #252 holding.
  • Los Angeles Capital Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 52 quarters since.
  • Los Angeles Capital Management's Gilead Sciences position peaked at $427M in Q3 2025.
  • 2,311 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.